Faeth Therapeutics (FTH) Stock Price, News & Analysis
Ticker history: SNSE became FTH (Faeth Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View SNSE history.
Why is FTH Stock Up Today?
AI-generated explanation by Rhea-AI, written on at . How Rhea-AI works. Not financial advice.
What Changed
Price Move History
- Daily moves over 5%
- 93 252 sessions, November 5, 2025 to November 5, 2026
- Largest daily move
- +187.5% close of February 18, 2026
- 1-year change
- +124.6% closing prices, November 5, 2025 to November 5, 2026
- 1-month change
- -26.5% closing prices, October 5, 2026 to November 5, 2026
Company Description
Faeth Therapeutics (NASDAQ: FTH) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $528.5M.
FTH has gained 124.6% over the past year. The last closing price was $19.92.
For FY2025, Faeth Therapeutics reported net income of -$21.1M and diluted earnings per share of -$16.72.
This page collects what Stock Titan holds for FTH, including price data, latest news, SEC filings, financial highlights, upcoming events, and short interest trends.
Stock Performance
Faeth Therapeutics (FTH) closed at $19.92 on November 5, 2026. Over the past 12 months, the price has gained 124.6%.
FTH Metrics & Rankings
Price returns through November 5, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Faeth Therapeutics has 10 recent news articles, with the latest published yesterday. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, management. View all FTH news →
SEC Filings
Faeth Therapeutics has filed 10 recent SEC filings, including 3 Form 4, 3 Form 8-K, 2 Form 3, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all FTH SEC filings →
Financial Highlights
Faeth Therapeutics reported operating income of -$22.3M in FY2025, and net income was -$21.1M. Diluted earnings per share stood at -$16.72. The company generated -$20.5M in operating cash flow. The current ratio was 5.06, measuring current assets divided by current liabilities.
Upcoming Events
Interim breast cancer data
Interim Phase 1b/2 readout
PIK-101 breast data
Options full vesting
Inducement Option Expiry
Option expiration
Option Expiration Date
Faeth Therapeutics has 7 upcoming scheduled events. The next event, "Interim breast cancer data", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the FTH stock price.
Short Interest History
Short interest in Faeth Therapeutics (FTH) currently stands at 2.3 million shares, up 12.3% from the previous reporting period, representing 9.5% of the float. Since June 2026, short interest has increased by 197.4%.
Days to Cover History
Days to cover for Faeth Therapeutics (FTH) currently stands at 7.8 days, up 114.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 2.8 to 7.8 days.
FTH Company Profile & Sector Positioning
Faeth Therapeutics (FTH) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing FTH often look at related companies in the same sector, including Neurogene, Inc. (NGNE), Entera Bio Ltd. (ENTX), Puma Biotechnology Inc (PBYI), Valneva SE (VALN), and Capricor Therapeutics Inc (CAPR). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate FTH's relative position within its industry.
Faeth Therapeutics (FTH) disclosed inducement options for three new employees, but the 68,000-share grant is a modest hiring-related award.